Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPGNASDAQ:ARWRNASDAQ:HRMYNASDAQ:VERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$25.50+6.7%$19.91$16.50▼$26.13$2.22BN/A78,287 shs63,807 shsARWRArrowhead Pharmaceuticals$13.34+2.5%$14.72$9.57▼$30.41$1.83B0.991.44 million shs1.04 million shsHRMYHarmony Biosciences$29.43+1.8%$32.15$26.47▼$41.61$1.66B0.8575,366 shs399,313 shsVERVVerve Therapeutics$5.78+5.7%$5.40$2.86▼$9.31$513.24M1.861.75 million shs3.05 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International+6.69%+36.22%+38.14%+2,549,999,900.00%+2,549,999,900.00%ARWRArrowhead Pharmaceuticals+2.54%+18.68%-9.44%-35.74%-42.72%HRMYHarmony Biosciences+1.83%+3.41%-10.79%-22.57%+0.68%VERVVerve Therapeutics+5.67%+25.93%-1.03%-26.93%-12.16%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AN/AN/AN/AARWRArrowhead Pharmaceuticals3.4902 of 5 stars3.31.00.03.43.42.50.0HRMYHarmony Biosciences4.6992 of 5 stars3.53.00.00.04.04.24.4VERVVerve Therapeutics3.1412 of 5 stars4.50.00.00.03.33.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/AARWRArrowhead Pharmaceuticals 2.60Moderate Buy$41.44210.68% UpsideHRMYHarmony Biosciences 3.00Buy$53.3381.22% UpsideVERVVerve Therapeutics 3.00Buy$25.75345.50% UpsideCurrent Analyst Ratings BreakdownLatest VERV, AAPG, ARWR, and HRMY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2025VERVVerve TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $24.004/15/2025VERVVerve TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight4/15/2025VERVVerve TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$32.00 ➝ $39.004/14/2025VERVVerve TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $25.004/8/2025HRMYHarmony BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.004/8/2025HRMYHarmony BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.003/27/2025AAPGAscentage Pharma Group InternationalJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight3/25/2025VERVVerve TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/25/2025VERVVerve TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/18/2025HRMYHarmony BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$42.00 ➝ $44.003/4/2025VERVVerve TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$17.00 ➝ $15.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$980.65M2.26N/AN/AN/A∞ARWRArrowhead Pharmaceuticals$2.50M732.72N/AN/A$1.54 per share8.66HRMYHarmony Biosciences$714.73M2.36$2.20 per share13.38$7.97 per share3.69VERVVerve Therapeutics$32.33M15.87N/AN/A$7.31 per share0.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group InternationalN/AN/A0.00∞N/AN/AN/AN/AN/AARWRArrowhead Pharmaceuticals-$599.49M-$5.17N/AN/AN/AN/A-236.60%-64.09%5/8/2025 (Estimated)HRMYHarmony Biosciences$128.85M$2.5113.959.460.4717.98%23.16%14.24%4/29/2025 (Estimated)VERVVerve Therapeutics-$200.07M-$2.35N/AN/AN/A-807.65%-35.23%-27.65%5/14/2025 (Estimated)Latest VERV, AAPG, ARWR, and HRMY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025VERVVerve Therapeutics-$0.71N/AN/AN/AN/AN/A5/8/2025Q2 2025ARWRArrowhead Pharmaceuticals-$0.06N/AN/AN/A$116.27 millionN/A4/29/2025Q1 2025HRMYHarmony Biosciences$0.59N/AN/AN/A$184.26 millionN/A2/27/2025Q4 2024VERVVerve Therapeutics-$0.72-$0.58+$0.14-$0.58$3.94 million$13.08 million2/25/2025Q4 2024HRMYHarmony Biosciences$0.74$0.85+$0.11$0.85$201.25 million$201.30 million2/10/2025Q1 2025ARWRArrowhead Pharmaceuticals-$0.42-$1.39-$0.97-$1.39$19.05 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/AVERVVerve TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group InternationalN/AN/AN/AARWRArrowhead Pharmaceuticals7.276.096.09HRMYHarmony Biosciences0.283.243.20VERVVerve TherapeuticsN/A13.0513.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AARWRArrowhead Pharmaceuticals62.61%HRMYHarmony Biosciences86.23%VERVVerve Therapeutics97.11%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AARWRArrowhead Pharmaceuticals4.30%HRMYHarmony Biosciences23.60%VERVVerve Therapeutics19.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60087.07 millionN/AN/AARWRArrowhead Pharmaceuticals400137.32 million120.68 millionOptionableHRMYHarmony Biosciences20057.35 million39.47 millionOptionableVERVVerve Therapeutics11088.80 million68.32 millionOptionableVERV, AAPG, ARWR, and HRMY HeadlinesRecent News About These CompaniesVerve Therapeutics, Inc. (NASDAQ:VERV) Given Average Recommendation of "Buy" by AnalystsApril 21, 2025 | marketbeat.comWhy Verve Therapeutics Zoomed 40% Higher This WeekApril 18, 2025 | fool.comVerve Therapeutics (NASDAQ:VERV) Upgraded at Cantor FitzgeraldApril 18, 2025 | americanbankingnews.comVerve Therapeutics Sees Unusually Large Options Volume (NASDAQ:VERV)April 17, 2025 | marketbeat.comGuggenheim Raises Verve Therapeutics (NASDAQ:VERV) Price Target to $24.00April 17, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Upgraded to Overweight at Cantor FitzgeraldApril 17, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Stock Price Expected to Rise, Canaccord Genuity Group Analyst SaysApril 17, 2025 | marketbeat.comBiotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More NewsApril 17, 2025 | finance.yahoo.comVerve’s One-Time Gene Editor Cuts LDL by Nearly 70% in Early TrialApril 17, 2025 | managedhealthcareexecutive.comHC Wainwright Forecasts Strong Price Appreciation for Verve Therapeutics (NASDAQ:VERV) StockApril 16, 2025 | marketbeat.comJ.P. Morgan Sticks to Their Hold Rating for Verve Therapeutics (VERV)April 16, 2025 | markets.businessinsider.comVerve Therapeutics (NASDAQ:VERV) Given New $24.00 Price Target at GuggenheimApril 16, 2025 | americanbankingnews.comCanaccord Genuity Group Issues Positive Forecast for Verve Therapeutics (NASDAQ:VERV) Stock PriceApril 16, 2025 | americanbankingnews.comOne-off gene-editing therapy could permanently lower cholesterolApril 16, 2025 | newscientist.comVerve extends gains as Cantor Fitzgerald upgrades on data for cholesterol drugApril 15, 2025 | msn.comVerve Therapeutics price target raised to $24 from $18 at GuggenheimApril 15, 2025 | markets.businessinsider.comCantor upgrades Verve Therapeutics to Overweight after positive dataApril 15, 2025 | markets.businessinsider.comVERV Stock Soars on Superior Efficacy in Phase I Cholesterol StudyApril 15, 2025 | zacks.comWhy Verve Therapeutics Is Skyrocketing TodayApril 15, 2025 | fool.comVerve Therapeutics price target raised to $25 from $15 at H.C. WainwrightApril 15, 2025 | markets.businessinsider.comVerve's 2nd swing at PCSK9 editing yields clean safety profile, teeing up Lilly opt-in decisionApril 14, 2025 | fiercebiotech.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeat3 Stocks Near 52-Week Lows With Strong Rebound PotentialBy Gabriel Osorio-Mazilli | March 31, 2025View 3 Stocks Near 52-Week Lows With Strong Rebound PotentialAI Takes Over Search: Is Google's Dominance At Risk?By Ryan Hasson | April 7, 2025View AI Takes Over Search: Is Google's Dominance At Risk?VERV, AAPG, ARWR, and HRMY Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$25.50 +1.60 (+6.69%) As of 04/24/2025 04:00 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Arrowhead Pharmaceuticals NASDAQ:ARWR$13.34 +0.33 (+2.54%) As of 04/24/2025 04:00 PM EasternArrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Harmony Biosciences NASDAQ:HRMY$29.43 +0.53 (+1.83%) As of 04/24/2025 04:00 PM EasternHarmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Verve Therapeutics NASDAQ:VERV$5.78 +0.31 (+5.67%) As of 04/24/2025 04:00 PM EasternVerve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Now Is the Time to Buy ServiceNow—The Rebound Is Real Seismic Shift at Intel: Massive Layoffs Precede Crucial Earnings Rocket Lab Lands New Contract, Builds Momentum Ahead of Earnings Netflix’s Trillion-Dollar Baby Ambition: Realistic or Ridiculous? Chip Giant ASML Gets New Price Targets With Big Upside Salesforce Is Ready to Rebound With Analysts Forecasting Upside What's Behind Bill Ackman Buying Hertz Stock? S&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
